Author: Matthew Nelson|| Date Published: December 20, 2019
The Department of Health and Human Services has awarded Paratek Pharmaceuticals a potential a five-year, $169M contract to further develop an antibiotic drug as a potential treatment for inhalation anthrax.
HHS said Wednesday its Biomedical Advanced Research and Development Authority will provide technical services and funds to help Paratek carry out research and manuacturing efforts for the Nuzyra drug, generically known as omadacycline.
The contract marks the department’s first award under Project BioShield, which incentivizes pharmaceutical companies to produce medical products meant to help the government counter biological, chemical, radiological and nuclear threats.
The Food and Drug Administration approved oral and intravenous forms of Nuzyra for adults who suffer from community-acquired pneumonia and acute skin infection.
Boston-based Paratek aims to secure emergency use authorization for antibiotic treatment of anthrax lung infections. BARDA will buy an initial supply if the company obtains FDA approval for expanded use of the drug.
Brian Meyer, federal field chief technology officer at Axonius Federal, said cybersecurity asset management could help government agencies make dozens…
“Technology transformation company Red River has acquired Invictus International Consulting to expand its cybersecurity and enterprise modernization capabilities to support…
Synergy ECP, a software engineering, cybersecurity and systems engineering services provider, has acquired NetServices, a company offering secure, mission-focused technology services. The…
Precision Aerospace & Defense Group and FACT II Acquisition, a special purpose acquisition company, have signed a definitive business combination agreement to…
LMI has announced the acquisition of intellectual property and advanced capabilities to broaden its in-transit visibility and asset tracking services for…
